Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.02 +0.24 (+0.51%)
Streaming Delayed Price Updated: 1:53 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 695,374
Open 47.64
Bid (Size) 48.02 (6)
Ask (Size) 48.03 (3)
Prev. Close 47.78
Today's Range 47.56 - 48.04
52wk Range 45.22 - 58.97
Shares Outstanding 1,250,690,553
Dividend Yield 3.96%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing. 
Via Benzinga
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry. 
Via Benzinga

Performance

YTD
-3.95%
-3.95%
1 Month
-10.50%
-10.50%
3 Month
-13.03%
-13.03%
6 Month
-4.64%
-4.64%
1 Year
+3.17%
+3.17%

More News

Read More
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Via Benzinga
Exposures Product Safety
Sanofi's Earnings Outlook
Via Benzinga
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Via Benzinga
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Via Benzinga
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Via Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
NASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Via Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Via Benzinga
Exposures Product Safety
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
Why Sanofi Stock Flew Higher on Friday
Via The Motley Fool
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Via Benzinga
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Via Investor's Business Daily
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Via Benzinga
Markets Mixed Again; DECK, SKX Beat After The Bell
Via Talk Markets
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Via Benzinga
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
Via The Motley Fool
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.